Sanofi Pasteur said The Dengvaxia vaccine was found to have a possible harmful impact on individuals who did not previously have dengue. Healthcare professionals here have been issued advisories on a dengue vaccine which could be harmful to individuals with no prior dengue experience.
From The Straits Times, the Health Sciences Authority (HSA) about the vaccine Dengvaxia said that all healthcare here have been issued advisories on this vaccine. The authority included that it will additionally strengthen the warnings and recommendations in the prescribing data of the vaccine, and closely monitor it to ensure its proceeded with efficacy and safety.
Dengvaxia was found to have a possible harmful impact when used on individuals who did not already have dengue. The individuals who were vaccinated and later became infected could have “more cases of severe disease”, a month ago said by the manufacturer, French pharmaceutical giant Sanofi Pasteur.
Whenever asked, HSA said there was one report of a male patient who developed a rash three days after being vaccinated, however he has since recovered. It has had no other reports of adverse reactions to Dengvaxia. In Singapore since March, Dengvaxia is the world’s first dengue antibody has been available after HSA approved its utilization in patients between 12 and 45 years of age in October a year ago.
In those days, HSA flagged the potential risk of severe dengue after reviewing information from Sanofi. It informed healthcare professionals of the risk and suggested that patients consult physicians before getting the vaccine. Educational materials and the package insert of Dengvaxia carried data on the risk. Blood tests to recognize previous dengue infection were also made available at major hospitals here.
HSA said it is currently working with Sanofi to “Strengthen the Package Insert” to include a warning of an increased risk of hospitalization for dengue and clinically severe dengue in vaccinated individuals not previously infected by dengue. Nonetheless, in its alert, Sanofi had included that for those already infected, Dengvaxia “Provides persistent benefit against dengue fever”.
HSA noticed that dengue vaccination is not a part of the national immunisation program, which means the vaccine is given to people just when the benefits outweigh the risk.